Back to discover
Drug

Buthionine Sulfoximine

In clinical development
Emerging researchEarly-to-mid development

Also known as Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, DL-buthionine-(S,R)-sulfoximine, Buthionine sulfoxamine.

RxNorm19877ChEMBLCHEMBL1256575UNIILW4108Q0BV
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

PILOT STUDY OF BUTHIONINE SULFOXIMINE (BSO) IN COMBINATION WITH MELPHALAN FOR HIGH RISK NEUROBLASTOMA PATIENTS

Clinical trial2024-11-20Completed · ClinicalTrials.gov

Increasing glutathione levels by a novel posttranslational mechanism inhibits neuronal hyperexcitability.

Research2023-09-21Redox biology

Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)

Clinical trial2016-04-01Completed · ClinicalTrials.gov

An Open-Label, Multicenter, Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic Buthionine Sulfoximine (BSO) in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma

Clinical trial2015-03-13Withdrawn · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Buthionine Sulfoximine
Aliases & brands
Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-DL-buthionine-(S,R)-sulfoximineButhionine sulfoxamine
RxNorm CUI
19877
ChEMBL ID
CHEMBL1256575
UNII
LW4108Q0BV

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2016
2
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 3
Phase 13

Recent completions

Trials that read out recently, adding to the completed evidence base.

Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)

CompletedPH INew Approaches to Neuroblastoma Therapy Consortiumn=312016

PILOT STUDY OF BUTHIONINE SULFOXIMINE (BSO) IN COMBINATION WITH MELPHALAN FOR HIGH RISK NEUROBLASTOMA PATIENTS

CompletedPH INew Approaches to Neuroblastoma Therapy Consortium

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Glutathione1Zebrafish1
Journals, researchers & institutions
Top journals
  • Redox biology1
Leading researchers
  • Banerji R1
  • Fabisiak T1
  • Fulton RE1
  • Huynh CQ1
  • Liang LP1
  • McElroy PB1
  • Patel M1
  • Roede JR1
Leading institutions
free-text, unnormalised
  • University of Colorado1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Glutathione

Studied across the same disease area as Buthionine Sulfoximine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials